glatiramer acetate depot

Glatiramer acetate depot is a long-acting formulation of glatiramer acetate, designed for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary progressive MS. Unlike standard daily or thrice-weekly injections, the depot formulation allows for administration once every four weeks, improving convenience and potentially adherence. The mechanism of action is not fully understood but is believed to involve modulation of immune processes implicated in MS pathogenesis. Glatiramer acetate acts as a decoy by mimicking myelin basic protein, thereby diverting autoimmune responses away from native myelin and promoting regulatory T cell activity that suppresses inflammation. The drug has demonstrated sustained safety and tolerability in clinical trials, with ongoing phase 3 studies for relapsing MS and phase 2a studies for progressive MS[2][8][6].

Brand names

GA Depot

Other names

glatiramer acetate depotGA Depot